David G Soergel Selected Research

GTP-Binding Proteins (G-Protein)

1/2019	APOLLO-2: A Randomized, Placebo and Active-Controlled Phase III Study Investigating Oliceridine (TRV130), a G Protein-Biased Ligand at the μ-Opioid Receptor, for Management of Moderate to Severe Acute Pain Following Abdominoplasty.
1/2019	APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy.
1/2018	Oliceridine (TRV130), a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. I: Development of a Pharmacokinetic/Pharmacodynamic Model.
1/2018	Oliceridine, a Novel G Protein-Biased Ligand at the μ-Opioid Receptor, Demonstrates a Predictable Relationship Between Plasma Concentrations and Pain Relief. II: Simulation of Potential Phase 3 Study Designs Using a Pharmacokinetic/Pharmacodynamic Model.
1/2017	A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (μ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty.
1/2016	A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain.
9/2013	The β-arrestin-biased ligand TRV120023 inhibits angiotensin II-induced cardiac hypertrophy while preserving enhanced myofilament response to calcium.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David G Soergel Research Topics

Disease

8	Heart Failure 12/2019 - 11/2011
6	Pain (Aches) 01/2022 - 09/2014
6	Acute Pain 01/2020 - 03/2014
3	Postoperative Pain 01/2019 - 01/2017
3	Vomiting 01/2019 - 09/2014
3	Nausea 01/2019 - 09/2014
2	Dyspnea (Shortness of Breath) 08/2017 - 03/2015
2	Respiratory Insufficiency (Respiratory Failure) 09/2014 - 03/2014
1	Body Weight (Weight, Body) 01/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 10/2013
1	Cardiomegaly (Heart Hypertrophy) 09/2013

Drug/Important Bio-Agent (IBA)

12	LigandsIBA 01/2019 - 11/2011
7	Morphine (MS Contin)FDA LinkGeneric 01/2020 - 03/2014
7	GTP-Binding Proteins (G-Protein)IBA 01/2019 - 09/2013
7	((3- methoxythiophen- 2- yl)methyl)((2- (9- (pyridin- 2- yl)- 6- oxaspiro(4.5)decan- 9- yl)ethyl))amineIBA 01/2019 - 09/2014
6	Analgesics (Analgesic Drugs)IBA 01/2022 - 03/2014
6	Opioid Receptors (Opioid Receptor)IBA 01/2019 - 09/2014
5	Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OHIBA 02/2018 - 11/2011
3	Opioid Analgesics (Opioids)IBA 01/2019 - 09/2014
3	Angiotensin IIIBA 09/2013 - 11/2011
3	ArrestinIBA 09/2013 - 11/2011
2	Type 1 Angiotensin ReceptorIBA 02/2018 - 08/2017
1	Oxycodone (Oxycontin)FDA LinkGeneric 01/2022
1	ReninIBA 12/2019
1	Cytochrome P-450 CYP2D6 (CYP2D6)IBA 01/2018
1	Brain Natriuretic Peptide (Natrecor)FDA Link 03/2015
1	Angiotensin Receptors (Angiotensin II Receptor)IBA 03/2015
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 10/2013
1	CalciumIBA 09/2013
1	Losartan (Cozaar)FDA LinkGeneric 09/2013
1	sarcosine- arginyl- valyl- tyrosyl- lysyl- histidyl- prolyl- alanineIBA 09/2013
1	SodiumIBA 09/2013
1	Furosemide (Lasix)FDA LinkGeneric 09/2012

Therapy/Procedure

4	Analgesia 01/2019 - 09/2014
3	Therapeutics 08/2017 - 10/2013
2	Abdominoplasty 01/2019 - 01/2017
2	Length of Stay 08/2017 - 03/2015
1	Patient-Controlled Analgesia (Analgesia, Patient Controlled) 01/2017
1	Patient Readmission 03/2015